illumina inc (ILMN) Key Developments
Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
Oct 1 15
Amoy Diagnostics Co. Ltd. and Illumina Inc. announced a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China. Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina’s next-generation sequencing platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy. The collaboration reflects the commitment of both companies to provide integrated solutions to meet clinical needs in China.
Illumina Inc. Launches TruSight Tumor OncoPanel
Sep 29 15
Illumina Inc. announced that it has launched TruSight Tumor 15, a next-generation sequencing (NGS) panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. TruSight Tumor 15 is optimized for low input DNA from tissue preserved in formalin and paraffin. The new sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin embedded (FFPE) tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs. When paired with the Illumina MiSeq system, the panel delivers high-quality sequencing with key content and features needed for tumor analysis in translational research. TruSight Tumor 15 offers a sample-to-data solution for research of common somatic variants. Simple sample-to-data workflow optimized for the MiSeq instrument will drive greater lab operational efficiency by replacing the cost and resource intensive practice of iterative single gene analysis; Focused gene content was informed by pharmaceutical partners, an independent consortia of key opinion leaders and the needs of pharmaceutical clinical researchers to identify relevant somatic variants in common solid tumors; Streamlined multiplex PCR-based library prep method, with limited hands on time, produces high-quality data in approximately 36 hours from extracted DNA to result; Highly sensitive assay detects somatic mutations at 5% variant frequency and maximizes sample success with 20 ng of DNA isolated from FFPE samples. TruSight Tumor 15 is available for order now and will ship in fourth quarter of 2015.
Memorial Sloan Kettering Cancer Center and Illumina Launch Comprehensive Circulating Tumor DNA Program
Sep 16 15
Memorial Sloan Kettering Cancer Center and Illumina Inc. announced a collaboration to conduct research studies that are critical to understanding the biology of circulating tumor DNA (ctDNA). The studies aim to inform the development of new strategies to diagnose and monitor cancer and to help establish ctDNA as an important marker in the study and eventual treatment of cancer. MSK and Illumina will conduct research trials designed to answer biological and clinical questions about ctDNA in multiple cancer types. MSK will collect samples, and Illumina will apply its sequencing technology to detect ctDNA in those samples. The program will work to validate a ctDNA assay to demonstrate correlation between ctDNA signal and cancer burden.
Illumina Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 01:00 PM
Sep 16 15
Illumina Inc. Presents at The Redefining Early Stage Investments (RESI) Conference 2015, Sep-16-2015 01:00 PM. Venue: Boston, Massachusetts, United States. Speakers: Charles Moehle, VP of Business Development & Licensing.
Burning Rock and Illumina, Inc. Collaborate on Molecular Diagnostics for Oncology
Aug 25 15
Burning Rock and Illumina Inc. announced they have entered into an agreement whereby Burning Rock will develop advanced clinical applications for molecular diagnostics in oncology based on Illumina’s next-generation sequencing (NGS) technology. The collaboration highlights the ever-increasing importance of genomics to improve healthcare in China. In recent years, NGS has evolved rapidly and is widely regarded as an essential technology for enabling precision medicine. The collaboration between Burning Rock and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market by combining Illumina sequencing technology with Burning Rock’s advanced clinical application development capabilities. In particular, the two companies will work together to develop a user-friendly, oncology molecular diagnostic kit for the Chinese market. As part of the agreement, Burning Rock will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.